Insurance Coverage for Psychedelic-Assisted Therapy in Canada (2026 Hub)

There is no single "psychedelic therapy benefit" in Canada. Coverage depends on the substance, the access pathway, your insurer or government program, and your province. This hub maps what is and is not covered across ketamine, Spravato, psilocybin, and MDMA, so you can find the pathway that fits your situation.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334 on 2026-05-27.

Key takeaways

• Spravato (intranasal esketamine) is the most likely privately covered option. It is the only Health Canada-approved psychedelic-assisted-therapy product (approved May 2020 for treatment-resistant depression in adults 18 to 64). Private prior-authorization pathways exist, including a federal Public Service Health Care Plan (PSHCP) route.
• Off-label ketamine the drug has structured public pathways through Veterans Affairs Canada, WSIB Ontario, and WCB Alberta, but is generally not on private drug formularies.
• Veterans Affairs Canada covers ketamine as a drug, not as therapy. As of its December 2024 position, VAC funds the ketamine medication for service-related conditions but does not fund ketamine-assisted psychotherapy, psilocybin-AT, or MDMA-AT.
• Psilocybin and MDMA are accessible only through Health Canada authorization granted on a case-by-case basis and initiated by a physician, and are largely uncovered. Quebec has one psilocybin-specific public-funding precedent (Farzin/Stephan, December 2022), not a routine benefit.
• Public drug plans generally do not list Spravato. A national do-not-reimburse recommendation in December 2020 is the upstream reason most provincial plans exclude it.
• Most figures here are volatile. Dollar amounts, form versions, and per-insurer rules change often. Coverage criteria and amounts vary; confirm current details directly with the relevant insurer or program before you rely on them.

If you want to map your coverage to a specific pathway, you can book a free 15-minute information call to discuss eligibility with ATMA CENA's clinical team.

The Canadian coverage map at a glance

The single most useful way to read this landscape is as a matrix: each cell is a combination of who pays and which substance. The table below is a starting reference, not a guarantee of coverage in any individual case. Coverage decisions are made plan by plan and patient by patient, and coverage criteria and amounts vary, so confirm current details directly with the insurer or program.

Who pays	Spravato (esketamine)	Off-label ketamine (drug)	Psilocybin	MDMA
Private extended health (prior auth)	May be covered for documented TRD; confirm per plan	Generally not on formularies	Drug not covered; therapy fees may be partial	Drug not covered; therapy fees may be partial
PSHCP / Canada Life (federal public servants)	Prior-auth pathway available; confirm with plan	Drug generally not covered	Not covered	Not covered
Alberta Blue Cross PAT (Mar 25, 2024)	Inclusion not stated publicly; confirm with insurer	Covered as ketamine-assisted therapy	Not currently covered; confirm with insurer	Not currently covered; confirm with insurer
Veterans Affairs Canada	Covers the drug for service-related TRD	Covers the drug for service-related TRD / chronic pain	Not covered	Not covered
WSIB Ontario	Esketamine on select formularies, prior auth	Ketamine on several formularies, prior auth	Not formally listed	Not formally listed
WCB Alberta	Case-by-case, written application	Case-by-case, written application	Not formally listed	Not formally listed
WorkSafeBC	Case-by-case	Case-by-case	Not formally listed	Not formally listed
Quebec RAMQ	Non-benefit (INESSS refus, Nov 2020)	Non-benefit	Precedent only (Farzin/Stephan, Dec 2022)	Not covered
Other provincial drug plans	Generally non-benefit	Generally non-benefit	Non-benefit	Non-benefit

VAC covers the ketamine drug but not the integrated psychotherapy; this distinction is explained in Section 4. Workers' compensation pathways apply only to compensable, work-related injuries.

How to read this article

Your access pathway depends mostly on the coverage you already hold, not on the substance you are interested in. The article is organized by patient profile:

• Section 1: Private extended-health benefits (most employees of mid-to-large employers)
• Section 2: Federal public servants (PSHCP / Canada Life)
• Section 3: Alberta Blue Cross psychedelic-assisted-therapy coverage
• Section 4: Veterans (Veterans Affairs Canada)
• Section 5: Injured workers (workers' compensation)
• Section 6: Provincial public drug plans
• Section 7: Out-of-pocket, when no coverage applies

For substance-specific cost detail, see Ketamine Therapy Cost in Canada, Psilocybin-Assisted Therapy Cost in Canada, and MDMA-Assisted Therapy Cost in Canada.

Section 1: Private extended-health benefits {#private}

If you have private extended-health benefits, your most realistic pathway depends on the substance. Spravato is the form most likely to be reimbursed because it is the only Health Canada-approved product in this category. Off-label ketamine the drug is rarely on private formularies. For psilocybin and MDMA, the drug itself is essentially never covered, though the psychotherapy hours around treatment may be partly reimbursable as standard psychotherapy where your plan covers a registered profession. None of this is automatic; private plans require prior authorization and apply their own criteria.

Spravato, the most likely covered

Spravato (intranasal esketamine) was approved by Health Canada in May 2020, in combination with an oral SSRI or SNRI, for treatment-resistant major depressive disorder in adults aged 18 to 64; initiation is not recommended in adults 65 and older [Health Canada 2020]. Because it is an approved product, several private insurers maintain prior-authorization pathways for documented TRD. Specific forms, criteria, and reimbursement levels vary by insurer and plan, and the exact rules change; check your plan's current requirements directly. Documentation is typically required and often includes a TRD diagnosis with documented failure of two or more adequate antidepressant trials, a specialist consultation, and a treatment plan, though criteria vary by plan. Net out-of-pocket after reimbursement varies widely. Do not assume a specific list price; confirm the current cost with the dispensing pharmacy.

For the Spravato private-insurance deep dive, see Private Insurance Prior Authorization for Spravato.

Off-label ketamine, generally not on private formularies

Generic ketamine used off-label for psychiatric or pain indications is generally not covered by private drug plans, because off-label use without a Canadian psychiatric indication does not fit standard formulary criteria. Ketamine is approved by Health Canada as an anaesthetic; use for depression, anxiety, PTSD, and other mental-health indications is off-label and regulated by provincial medical regulators. The preparation and integration psychotherapy may be partly covered as standard psychotherapy when delivered by a registered profession, depending on your province and plan.

Psilocybin and MDMA, drug not covered

For both restricted-access substances, the drug is not covered by private insurance. Psychotherapy hours may be partly reimbursable as standard psychotherapy. See the compliance block below for how patient access to these substances works.

Section 2: Federal public servants (PSHCP / Canada Life) {#pshcp}

The Public Service Health Care Plan (PSHCP), administered by Canada Life, covers a large population of federal public servants, retirees, and dependants nationwide. For Spravato, PSHCP has a documented prior-authorization pathway; the specific form and its current version should be confirmed with the plan. Eligibility generally requires documented treatment-resistant depression with failed antidepressant trials, Spravato used alongside a concurrent oral antidepressant, and a specialist prescription, though the exact criteria vary and should be confirmed directly. PSHCP reimburses eligible drug expenses at its standard plan-established drug-benefit rate rather than a Spravato-specific rate [PSHCP 2024]. The PSHCP pathway exists independently of provincial formulary decisions because federal public-servant drug coverage is separately administered and is not bound by provincial listing choices. This makes it one of the more established private routes to an approved psychedelic-assisted-therapy product in Canada.

For the full walkthrough, see PSHCP / Canada Life Spravato Coverage.

Section 3: Alberta Blue Cross psychedelic-assisted-therapy coverage {#alberta-blue-cross}

On March 25, 2024, Alberta Blue Cross became the first insurance provider in Canada to formally cover psychedelic-assisted therapy within its health-coverage options [Alberta Blue Cross 2024]. ATMA CENA was a named partner in the announcement.

What was confirmed at launch:

• Coverage initially focused on ketamine-assisted therapy, available within group, workplace, and individual plans, subject to plan maximums and provider-eligibility requirements.
• The announcement described psilocybin and MDMA as future potential, dependent on those substances being legalized for therapy in Canada.

What is not publicly confirmed (verify before relying on it):

• Whether Spravato (esketamine) is included under this benefit is not addressed in public communications; confirm with Alberta Blue Cross.
• Whether 2026 scope has expanded beyond ketamine to psilocybin or MDMA has not been confirmed through any public update; confirm with Alberta Blue Cross.
• Which specific ketamine forms are eligible, and the prior-authorization workflow, are not detailed publicly; confirm at intake.

Watch out: Insurer scope and eligibility rules change without broad public notice. Confirm current Alberta Blue Cross psychedelic-assisted-therapy terms directly with the insurer or at intake before assuming any specific drug or substance is covered.

For the deep dive, see Alberta Blue Cross PAT Coverage.

Section 4: Veterans Affairs Canada {#vac}

Veterans Affairs Canada (VAC) draws a clear line that is easy to misread: it covers ketamine as a drug for service-related conditions, but it does not fund psychedelic-assisted psychotherapy. Per VAC's December 2024 position, VAC will consider funding ketamine infusion, oral ketamine, or Spravato for treatment-resistant depression or TRD co-existing with PTSD, and ketamine forms for chronic pain, when prescribed by a treating psychiatrist [VAC 2024]. VAC's stated rationale for excluding the therapy is that providing psychotherapy to someone in a drug-induced psychedelic state remains an emerging therapy without sufficient scientific evidence to meet its standard for reimbursement.

What this distinction means in practice

VAC pays for the ketamine medication administered as a pharmacological treatment. It does not pay for the structured psychotherapy component of ketamine-assisted psychotherapy (KAP). The same exclusion applies to psilocybin-assisted therapy and MDMA-assisted therapy: VAC does not currently fund either [VAC 2024]. Veterans accessing psilocybin-AT or MDMA-AT through Health Canada's case-by-case authorization pathway pay out-of-pocket or through other third-party coverage. If a program is structured as psychedelic-assisted psychotherapy rather than a pure drug administration, the psychotherapy portion would not be reimbursable under VAC's current policy even where the ketamine drug cost is covered.

Scale of VAC ketamine coverage

Public reporting has indicated that VAC reimburses a number of veterans for ketamine treatment each year, but the specific counts and average amounts change from year to year and are not something to rely on. Treat any single figure as historical context; confirm current fiscal data with VAC's most recent reporting before relying on it. VAC coverage for all forms requires a service-related diagnosis connected to eligible service.

For the deep dive, see VAC Coverage for Psychedelic-Assisted Therapy.

Section 5: Workers' compensation {#workers-comp}

Workers' compensation boards cover treatment only for compensable, work-related injuries, and their psychedelic-related pathways vary by province. The strongest formal listings are for ketamine.

WSIB Ontario: formulary listings with prior authorization

WSIB Ontario lists ketamine injection, with prior authorization, on several of its injury-specific formularies, and esketamine (Spravato) nasal spray, also with prior authorization, on a smaller number of them [WSIB 2023]. Both require prior authorization and a specialist prescription; confirm the current formulary listings and criteria directly with WSIB.

On the legislative side, Ontario's Bill 163 (Supporting Ontario's First Responders Act, 2016) established presumptive PTSD coverage for designated first responders such as police, firefighters, paramedics, and corrections officers. In October 2024, a separate law, Bill 190 (Working for Workers Five Act, 2024), which received Royal Assent on October 28, 2024, extended that presumptive coverage to wildland firefighters and wildland fire investigators [Ontario 2024]. Presumptive PTSD coverage speeds recognition of the underlying diagnosis; it does not auto-approve any specific treatment, so case-by-case prior authorization for ketamine still applies. Psilocybin and MDMA are not formally listed on WSIB formularies.

WCB Alberta: case-by-case, not a formulary benefit

WCB Alberta approves ketamine and esketamine for treatment-resistant depression and work-related chronic pain on a case-by-case basis, not as a standard formulary benefit. Each request requires a written application from an approved specialist (such as a neurologist, psychiatrist, physiatrist, or chronic-pain specialist), the board's required application form, medical-consultant review, and supervisor approval before treatment [WCB Alberta 2026]. Confirm the current forms and criteria directly with WCB Alberta. Psilocybin and MDMA are not formally listed.

WorkSafeBC and other provinces

WorkSafeBC reviews ketamine and other claims case-by-case; its Evidence-Based Practice Group has published cautious reviews on IV and oral ketamine for chronic non-cancer pain [WorkSafeBC 2025]. CNESST Quebec and the boards in Manitoba, Saskatchewan, and the Atlantic provinces generally handle these claims case-by-case, without formal listings comparable to WSIB Ontario.

For the deep dive, see Workers' Compensation for Psychedelic-Assisted Therapy.

Section 6: Provincial public drug plans {#provincial}

Provincial public drug plans generally do not cover psychedelic-assisted therapy. The upstream reason for Spravato is a national recommendation: the CADTH Canadian Drug Expert Committee (now CDA-AMC) issued a final do-not-reimburse recommendation for esketamine in treatment-resistant depression on December 18, 2020 [CDA-AMC 2020]. Because of that recommendation, Spravato remains a non-benefit across Canadian public drug formularies.

• Quebec (RAMQ / INESSS): INESSS recommended against listing Spravato in November 2020 (refus d'inscription), and that recommendation had not been reversed as of May 2026 [INESSS 2020]. The one exception in Quebec is a psilocybin-specific billing precedent: in December 2022, two Quebec physicians (Farzin and Stephan) billed RAMQ for psilocybin-assisted psychotherapy for a patient with a valid Health Canada authorization [TheraPsil]. This was a precedent enabled by advocacy, not a routine benefit, and it applies to psilocybin only. Confirm current RAMQ billing status with the treating physician before treatment. See Quebec RAMQ Coverage for Psychedelic Therapy.
• British Columbia (PharmaCare): BC PharmaCare issued a Do Not Reimburse decision for Spravato, dated August 3, 2021, consistent with the December 2020 national recommendation; no reversal was identified as of May 2026 [BC PharmaCare 2021].
• Ontario (ODB), Saskatchewan, Manitoba, and Atlantic provinces: generally non-benefit, consistent with the national recommendation; confirm individual provincial status directly.

For Alberta residents with ultra-resistant TRD, a separate public pathway exists. Edmonton's Misericordia and Grey Nuns hospitals operate a publicly funded outpatient IV ketamine program for treatment-resistant depression, covered through AHCIP for eligible Alberta residents with psychiatric referral [Chrenek 2023]. Capacity is limited. See Edmonton Misericordia / Grey Nuns Public Ketamine Program.

For the full provincial breakdown, see Provincial Drug Plans and Psychedelic Therapy.

Section 7: Out-of-pocket, when no coverage applies {#out-of-pocket}

When no insurance pathway applies, the cost depends on the substance and the program. Specific prices are volatile and should be confirmed directly; the substance cost articles carry the current bands.

• Ketamine: ATMA CENA's ketamine-assisted therapy is priced at $1,590 for the initial treatment and $800 for each additional medicine session, with discounted multi-session packages ranging from $2,390 to $6,500 and a $300 non-refundable deposit that begins intake. The price is inclusive of assessment and prescription, preparation therapy, intention-setting therapy, the medicine session, integration therapy, and follow-up care. See Ketamine Therapy Cost in Canada.
• Spravato without coverage: per-session cost varies; confirm the current list price with the dispensing pharmacy.
• Psilocybin: see Psilocybin-Assisted Therapy Cost in Canada for current bands.
• MDMA-AT: see MDMA-Assisted Therapy Cost in Canada for current bands.

How to find your coverage pathway

A practical way to narrow down your route:

1. Federal public servant or PSHCP-eligible? The PSHCP Spravato prior-authorization pathway is often the most accessible private prior-auth route. See Section 2.
2. Veteran with a service-related condition? VAC covers the ketamine drug, not the psychotherapy; it does not fund psilocybin-AT or MDMA-AT. See Section 4.
3. Injured worker with a compensable injury? Workers' compensation may apply. WSIB Ontario has the most formal listings. See Section 5.
4. Alberta resident with Alberta Blue Cross coverage? Ketamine-assisted therapy may be covered; confirm substance scope. See Section 3.
5. Alberta resident with ultra-resistant TRD? The AHCIP-funded Edmonton IV ketamine program may apply. See Section 6.
6. Private extended-health with mental-health benefits? A Spravato prior-auth pathway for documented TRD is the most likely route. See Section 1.
7. None of the above? Out-of-pocket. See Section 7.

Frequently asked questions

What is the most accessible private insurance pathway for psychedelic-assisted therapy in Canada?

For most people, it is Spravato (intranasal esketamine) for documented treatment-resistant depression through private prior authorization, because Spravato is the only Health Canada-approved product in this category. Federal public servants often use the PSHCP prior-authorization route. Other privately insured patients may have prior-auth pathways through their own insurers, but the specific forms, criteria, and reimbursement vary by plan and should be confirmed directly.

Why is Spravato more likely to be covered than off-label ketamine?

Spravato is Health Canada-approved for treatment-resistant depression in adults 18 to 64, so private prior-authorization pathways can align with an approved indication. Off-label generic ketamine has no approved Canadian psychiatric indication, so it does not fit standard formulary inclusion criteria and is generally not on private drug plans.

Does VAC cover psychedelic-assisted therapy for veterans?

VAC covers ketamine as a drug for service-related treatment-resistant depression or chronic pain when prescribed by a treating psychiatrist. As of its December 2024 position, VAC does not fund ketamine-assisted psychotherapy, psilocybin-assisted therapy, or MDMA-assisted therapy. The drug cost may be covered; the structured psychotherapy component is not.

Does Quebec RAMQ cover any psychedelic therapy?

There is a psilocybin-specific precedent. In December 2022, two Quebec physicians billed RAMQ for psilocybin-assisted psychotherapy for a patient with a valid Health Canada authorization. This was a precedent rather than a routine benefit, and it applies to psilocybin only. RAMQ does not list Spravato (INESSS recommended against it in November 2020), and there is no comparable precedent for ketamine-AT or MDMA-AT.

Does Alberta Blue Cross cover psilocybin and MDMA?

At its March 25, 2024 launch, Alberta Blue Cross coverage focused on ketamine-assisted therapy, with psilocybin and MDMA described as future potential dependent on those substances being legalized for therapy in Canada. Whether 2026 scope has changed, and whether Spravato is included, are not confirmed in public communications. Confirm current terms directly with Alberta Blue Cross.

What does WSIB Ontario cover for first responders with PTSD?

WSIB Ontario lists ketamine on several formularies and esketamine on a smaller number, each with prior authorization, for compensable injuries. Ontario's 2016 Bill 163 established presumptive PTSD coverage for designated first responders, and the October 2024 Bill 190 extended it to wildland firefighters and wildland fire investigators. Presumptive coverage speeds recognition of the PTSD diagnosis; it does not auto-approve any specific treatment, so case-by-case ketamine prior authorization still applies.

Is there any publicly funded psychedelic therapy in Canada?

Two established public pathways exist. Edmonton's Misericordia and Grey Nuns hospitals run an AHCIP-funded outpatient IV ketamine program for treatment-resistant depression for eligible Alberta residents. Quebec has a psilocybin billing precedent through RAMQ for a Health Canada-authorized patient. Both are capacity-limited and require referral.

Can I appeal a denied insurance application?

Yes. Most insurers and government programs have appeal processes, and the steps differ by program. Appeals typically require additional clinical justification, documentation of alternative treatment failures, or specialist consultation. Discuss next steps with your prescribing physician. For a structured walkthrough, see the appeals article linked below.

Compliance and disclaimers

Ketamine framing. Ketamine is approved by Health Canada as an anaesthetic. Use for depression, anxiety, PTSD, and other mental-health indications is off-label, regulated by provincial medical regulators (for example, CPSA in Alberta, CPSO in Ontario, CPSM in Manitoba, CMQ in Quebec).

Spravato scope. Esketamine (Spravato) is Health Canada-approved in combination with an oral SSRI or SNRI for treatment-resistant major depressive disorder in adults aged 18 to 64; initiation is not recommended in adults 65 and older.

Restricted-substance access. Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Legal patient access to psilocybin- or MDMA-assisted therapy requires Health Canada approval, granted on a case-by-case basis and initiated by a physician; it is not guaranteed. Such authorizations are primarily granted, for psilocybin, to adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness, and, for MDMA, to adults with PTSD.

Not financial or insurance advice. This article is educational and reflects publicly available information as of the last-updated date. It is not financial, insurance, tax, legal, or medical advice. Coverage rules, dollar figures, form versions, and eligibility criteria change frequently and vary by plan, province, and individual circumstances, so confirm current details directly with the relevant insurer, government program, or your prescribing physician before you make any coverage decision. Nothing here guarantees that any treatment will be covered or that any clinical outcome will result.

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

Sources

1. Health Canada (2020). Spravato (esketamine) Product Monograph and Drug Product Database entry. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
2. CDA-AMC / CADTH (2020). Esketamine (Spravato): CDEC Final Recommendation, December 18, 2020. https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0621%20Spravato%20-%20CDEC%20Final%20Recommendation%20December%2018,%202020_for%20posting.pdf
3. Canada Life (2024). PSHCP Spravato Prior Authorization. https://www.welcome.canadalife.com/pshcp
4. PSHCP (2024). Extended Health Provision: Drug Benefit. https://www.pshcp.ca/benefits/extended-health-provision/drug-benefit/
5. Alberta Blue Cross / ATMA CENA (2024). Psychedelic-assisted therapy coverage announcement, March 25, 2024. https://www.newswire.ca/news-releases/atma-cena-celebrates-groundbreaking-support-from-alberta-blue-cross-for-psychedelic-assisted-therapies-816961225.html
6. Veterans Affairs Canada (2024). Mental Health Benefits; December 2024 ministerial briefing on mental-health treatments. https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
7. WSIB Ontario (2023). Drug Formulary Listing Decision: Ketamine and Esketamine. https://www.wsib.ca/en/drug-formulary-listing-decision-ketamine-and-esketamine
8. Legislative Assembly of Ontario (2024). Bill 190, Working for Workers Five Act, 2024 (Royal Assent October 28, 2024). https://www.ola.org/en/legislative-business/bills/parliament-43/session-1/bill-190
9. WCB Alberta (2026). Procedures Manual: Pharmaceutical Ketamine and Esketamine. https://www.wcb.ab.ca/about-wcb/procedures-manual/pharmaceutical-ketamine-and-esketamine.html
10. WorkSafeBC (2025). Evidence-Based Practice Group: IV and Oral Ketamine for Chronic Non-Cancer Pain (2025 update). https://www.worksafebc.com/en/resources/health-care-providers/guides/issues-on-iv-ketamine-and-oral-ketamine-for-chronic-non-cancer-pain-2025-update
11. INESSS (2020). Spravato: Avis au ministre, November 2020. https://www.inesss.qc.ca/en/themes/medicaments/drug-products-undergoing-evaluation-and-evaluated/extract-notice-to-the-minister/spravato-5429.html
12. BC PharmaCare (2021). Drug Coverage Decision: Esketamine (Spravato), Do Not Reimburse, August 3, 2021. https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/decisions/esketamine_hydrochloride_spravato_dds.pdf
13. TheraPsil (2022). Quebec first province to cover costs of psilocybin-assisted psychotherapy. https://therapsil.ca/quebec-first-province-to-cover-costs-of-psilocybin-assisted-psychotherapy-done-by-two-physicians/
14. Chrenek, C. et al. (2023). Outpatient IV ketamine program for treatment-resistant depression in Edmonton, Alberta. Frontiers in Psychiatry, 14:1283733. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1283733/full
15. Health Canada. Requests involving psychedelic-assisted psychotherapy (physician-initiated, case-by-case access pathway). https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
16. CBC News (2024). Reporting on VAC ketamine reimbursement. https://www.cbc.ca/

Related articles in this cluster

• PSHCP / Canada Life Spravato Coverage
• Alberta Blue Cross PAT Coverage
• VAC Coverage for Psychedelic-Assisted Therapy
• Workers' Compensation for Psychedelic-Assisted Therapy
• Quebec RAMQ Coverage for Psychedelic Therapy
• Private Insurance Prior Authorization for Spravato
• Ketamine Therapy Cost in Canada

---

Last updated: 2026-05-27. This article is reviewed every 3 months because coverage details change frequently.